Other Events ·
RedHill Biopharma provided an update on the development of opaganib for Ebola virus disease amid a Bundibugyo…
RDHLRedHill Biopharma Ltd.
RedHill Biopharma provided an update on the development of opaganib for Ebola virus disease amid a Bundibugyo ebolavirus outbreak with 3,221 cases and 1,407 deaths. The company is finalizing development next steps and engaging in potential partnership discussions with the African Medicines Agency, the Ugandan Ministry of Health, Mbarara University of Science and Technology, and the DRC Scientific Advisory Committee. Opaganib is being evaluated as a host-directed antiviral add-on to remdesivir, supported by Phase 3 COVID-19 data showing a 70.2% mortality reduction and preclinical studies demonstrating synergistic effects. RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology.